Print

Durata Therapeutics, Inc. Announces Dalbavancin Production Capabilities and Signing of Global Manufacturing Agreement  
6/6/2011 11:01:59 AM

MORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics today announced the successful production of clinical supplies of dalbavancin, the Company’s lead product, at two top-tier manufacturing facilities. Durata also announced the signing of a global, multi-year agreement with one of these manufacturers. Dalbavancin is a long-acting, intravenous (IV) lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections (abSSSI). Additional details of the agreements were not disclosed.
//-->